Yoshioka Yusuke, Katsuda Takeshi, Ochiya Takahiro
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Jpn J Clin Oncol. 2018 Oct 1;48(10):869-876. doi: 10.1093/jjco/hyy120.
Over the past several years, considerable focus has been placed on the need for 'biomarkers'. However, traditional biomarkers, such as CEA or CA19-9, for gastrointestinal cancer do not provide sufficient sensitivity and specificity for diagnosing cancer. Moreover, these biomarkers cannot provide information regarding the individual variability of patients. Recently, extracellular vesicles (EVs) and extracellular microRNA (miRNA) have shown potential in cancer diagnosis because tumor cells have been shown to release EVs and miRNAs, which mirror their cellular origin, into circulation. Therefore, detection of tumor-specific EVs and extracellular miRNA in body fluids from cancer patients could serve as a non-invasive liquid biopsy for cancer diagnosis and monitoring. This review explores the potential contribution of liquid biopsy using EVs and extracellular miRNA to diagnosis and monitor cancer, including an assessment of prognosis and early detection of disease recurrence in patients with cancer.
在过去几年中,人们相当关注“生物标志物”的需求。然而,用于胃肠道癌的传统生物标志物,如癌胚抗原(CEA)或糖类抗原19-9(CA19-9),在诊断癌症时并未提供足够的敏感性和特异性。此外,这些生物标志物无法提供有关患者个体差异的信息。最近,细胞外囊泡(EVs)和细胞外微小RNA(miRNA)在癌症诊断中显示出潜力,因为已证明肿瘤细胞会将反映其细胞来源的EVs和miRNAs释放到循环中。因此,检测癌症患者体液中的肿瘤特异性EVs和细胞外miRNA可作为癌症诊断和监测的非侵入性液体活检。本综述探讨了使用EVs和细胞外miRNA进行液体活检对癌症诊断和监测的潜在贡献,包括对癌症患者预后评估和疾病复发早期检测。